Belfast · Northern Ireland
TheBELFAST HERALDLocal knowledge. National perspective.
Retrospective archiveHistorical reports were compiled from linked contemporaneous sources. Dates refer to the events covered.How the archive works
HealthPremium archive

Vaccine developer Novavax announces that their vaccine candidate is 89% effective in preventing severe COVID-19, based on trial data from the United Kingdom

Vaccine developer Novavax announces that their vaccine candidate is 89% effective in preventing severe COVID-19, based on trial data from the United Kingdom; their vaccine was less effective against new variants of the virus, based on data from South Africa.

By Belfast Herald Newsdesk1 min read

Herald Premium Archive

This report is for subscribers

Sign in or choose a plan to read this report and the complete Premium retrospective archive.

HealthVaccine developer Novavax announces that their vaccine candidate is 89% effective in preventing severe COVID-19, based on trial data from the United Kingdom

Vaccine developer Novavax announces that their vaccine candidate is 89% effective in preventing severe COVID-19, based on trial data from the United Kingdom; their vaccine was less effective against new variants of the virus, based on data from South Africa.

View Premium plansBrowse free archive reports